Zafgen will soon enter a Phase 3 trial for its obesity drug beloranib and expects to have a rich year for data in 2015, said the company's CEO Dr. Tom Hughes. Hughes said the upcoming trial will focus on the effects of beloranib on patients with Prader-Willi Syndrome, a rare genetic condition. Next year Hughes is planning trials focusing on patients with diabetes. He said beloranib works differently from drugs developed by competitors like Vivus because it does not alter brain chemistry. Finally, Hughes said the company has more than enough cash to reach its goal, expecting to have $95 million by the end of 2014.

More from Video

Jim Cramer: Will Apple or Amazon Become the World's First Trillion Dollar Stock?

Jim Cramer: Will Apple or Amazon Become the World's First Trillion Dollar Stock?

It's Dumb to Think Legalizing Weed Is Still a Political Issue

It's Dumb to Think Legalizing Weed Is Still a Political Issue

Video: How to Select Mutual Funds in Your 401(k)

Video: How to Select Mutual Funds in Your 401(k)

Racing Legend Mario Andretti Has Great Advice for Retirees

Racing Legend Mario Andretti Has Great Advice for Retirees

Arianna Huffington on Burnout, Tech-Life Balance and Why Amazon's CEO Agrees

Arianna Huffington on Burnout, Tech-Life Balance and Why Amazon's CEO Agrees